Humana (NYSE:HUM) Updates FY24 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of approx. $16.00 for the period, compared to the consensus EPS estimate of $16.35.

Analyst Ratings Changes

HUM has been the topic of several analyst reports. Mizuho dropped their price target on shares of Humana from $550.00 to $400.00 and set a buy rating on the stock in a research report on Friday, January 26th. UBS Group decreased their target price on shares of Humana from $334.00 to $326.00 and set a neutral rating on the stock in a research note on Thursday. TheStreet lowered Humana from a b rating to a c+ rating in a research report on Monday, January 8th. Barclays decreased their price target on shares of Humana from $356.00 to $310.00 and set an equal weight rating for the company in a research report on Tuesday, April 2nd. Finally, Bank of America reissued a neutral rating and issued a $342.00 price target (down from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of Hold and a consensus target price of $437.00.

Humana Trading Down 1.7 %

NYSE:HUM traded down $5.34 on Thursday, hitting $310.64. 611,462 shares of the stock were exchanged, compared to its average volume of 1,988,761. Humana has a 52 week low of $299.23 and a 52 week high of $541.21. The stock has a market capitalization of $37.48 billion, a price-to-earnings ratio of 15.68, a P/E/G ratio of 1.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. The company’s 50-day moving average price is $329.24 and its 200 day moving average price is $396.94.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 19.44% and a net margin of 2.34%. The company had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the prior year, the company earned $9.38 earnings per share. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, equities research analysts forecast that Humana will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio (DPR) is currently 17.86%.

Insider Transactions at Humana

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of Humana stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.